← Back to Analyst Consensus 
ASND Buy
Ascendis Pharma A/S
Current Price —
Implied Upside —
Analysts 28
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 26, 2026 | kodoqu | maintain | — | — | — |
| Sep 25, 2026 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $300 | 50% |
| Sep 15, 2026 | Raymond James | downgrade | Strong Buy → Outperform | $287 | 54% |
| Sep 2, 2026 | Oppenheimer | maintain | Outperform → Outperform | $312 | 52% |
| Sep 1, 2026 | Morgan Stanley | maintain | Overweight → Overweight | $273 | 54% |
| Sep 1, 2026 | Wedbush | reiterate | Outperform → Outperform | $327 | 58% |
| Aug 31, 2026 | B of A Securities | maintain | Buy → Buy | $304 | 53% |
| Aug 31, 2026 | Jefferies | maintain | Buy → Buy | $330 | 52% |
| Aug 31, 2026 | Stifel | maintain | Buy → Buy | $326 | 53% |
| Aug 31, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $344 | 44% |
| Aug 27, 2026 | HC Wainwright & Co. | initiate | — → Buy | $345 | 44% |
| Aug 19, 2026 | BMO Capital | initiate | — → Outperform | $319 | 53% |
| Aug 14, 2026 | TD Cowen | maintain | Buy → Buy | $341 | 54% |
| Aug 14, 2026 | RBC Capital | maintain | Outperform → Outperform | $290 | 55% |
| Aug 14, 2026 | Barclays | maintain | Overweight → Overweight | $329 | 53% |
| Jul 23, 2026 | Morgan Stanley | maintain | Overweight → Overweight | $275 | 54% |
| Jul 7, 2026 | RBC Capital | maintain | Outperform → Outperform | $280 | 55% |
| May 19, 2026 | Citigroup | initiate | — → Buy | $355 | 54% |
| May 15, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | $329 | 58% |
| May 11, 2026 | Barclays | maintain | Overweight → Overweight | $345 | 53% |
| May 8, 2026 | Wells Fargo | maintain | Overweight → Overweight | $326 | 54% |
| Apr 16, 2026 | B of A Securities | maintain | Buy → Buy | $292 | 53% |
| Apr 9, 2026 | Wedbush | reiterate | Outperform → Outperform | $273 | 58% |
| Mar 3, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Feb 12, 2026 | Oppenheimer | maintain | Outperform → Outperform | $262 | 52% |
| Feb 12, 2026 | Wedbush | maintain | Outperform → Outperform | $273 | 58% |
| Jan 30, 2026 | B of A Securities | maintain | Buy → Buy | $260 | 53% |
| Jan 28, 2026 | Barclays | initiate | — → Overweight | $342 | 53% |
| Jan 20, 2026 | RBC Capital | maintain | Outperform → Outperform | $250 | 55% |
| Jan 20, 2026 | Wells Fargo | maintain | Overweight → Overweight | $330 | 54% |
| Jan 9, 2026 | Wells Fargo | maintain | Overweight → Overweight | $322 | 54% |
| Jan 7, 2026 | TD Cowen | reiterate | Buy → Buy | $325 | 54% |
| Dec 11, 2025 | Stifel | maintain | Buy → Buy | $256 | 53% |
| Nov 18, 2025 | Wedbush | reiterate | Outperform → Outperform | $220 | 58% |
| Oct 17, 2025 | Raymond James | initiate | — → Strong Buy | $271 | 54% |
| Oct 13, 2025 | Cantor Fitzgerald | maintain | Overweight → Overweight | $254 | 50% |
| Oct 9, 2025 | JP Morgan | maintain | Overweight → Overweight | $264 | 54% |
| Sep 2, 2025 | B of A Securities | maintain | Buy → Buy | $230 | 53% |
| Aug 19, 2025 | JP Morgan | maintain | Overweight → Overweight | $260 | 54% |
| Aug 8, 2025 | Citigroup | maintain | Buy → Buy | $290 | 54% |
| Aug 8, 2025 | RBC Capital | maintain | Outperform → Outperform | $230 | 55% |
| Aug 8, 2025 | Wedbush | maintain | Outperform → Outperform | $220 | 58% |
| Aug 8, 2025 | UBS | maintain | Buy → Buy | $307 | 54% |
| Aug 8, 2025 | Cantor Fitzgerald | maintain | Overweight → Overweight | $203 | 50% |
| Aug 8, 2025 | Wells Fargo | maintain | Overweight → Overweight | $295 | 54% |
| Aug 8, 2025 | Stifel | maintain | Buy → Buy | $254 | 53% |
| Jul 29, 2025 | JP Morgan | maintain | Overweight → Overweight | $254 | 54% |
| Jul 11, 2025 | Citigroup | maintain | Buy → Buy | $243 | 54% |
| Jun 13, 2025 | Oppenheimer | maintain | Outperform → Outperform | $224 | 52% |
| Jun 9, 2025 | B of A Securities | maintain | Buy → Buy | $216 | 53% |
Price Target Trend
Jul 17, 2026 Oct 26, 2026
EPS Estimates
+1y —
0y —
0q —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days